CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 13, 2006--EPIX Pharmaceuticals, Inc. (NASDAQ: EPIX), a developer of innovative pharmaceuticals for magnetic resonance imaging (MRI), today announced that the United States Patent Office has issued U.S. Patent No. 6,991,775, a composition-of-matter patent providing coverage for a large family of peptides and peptide derivatives that bind with high specificity to fibrin, a protein found in blood clots. The patent is entitled "Peptide-based Multimeric Targeted Contrast Agents." As issued, its term extends through July 30, 2022. The patent covers EP-2104R, EPIX's investigational fibrin-binding imaging agent, which is completing Phase IIa clinical studies.
